MK-6598 / Merck (MSD) - LARVOL DELTA

Discovery and preliminary clinical findings of MK-6598, a potent and selective inhibitor of the immune checkpoint IL4I1 (AACR 2025) - P1 | "The only response was in a pt with mismatch repair-deficient endometrial cancer that progressed on prior pembro achieved a partial response after crossing over from MK-6598 monotherapy to MK-6598 plus pembro. These data suggest that despite its ability to inhibit IL4I1 protein, MK-6598 has limited antitumor activity as monotherapy or in combination with pembro in pts with previously treated advanced solid tumors."

Clinical • IO biomarker • Endometrial Cancer • Oncology • Solid Tumor • IL4 • IL4I1

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) (clinicaltrials.gov) - P1 | N=90 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2027 ➔ May 2025 | Trial primary completion date: Dec 2027 ➔ May 2025

Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Solid Tumor

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Monotherapy • Oncology • Solid Tumor

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

Combination therapy • Monotherapy • New P1 trial • Oncology • Solid Tumor